|Articles|December 1, 2004

Head-to-head study comparison

Tacrolimus bests pimecrolimus for AD population

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME